Top Markets
Coin of the day
TaiRx, Inc. TaiRx, Inc.

TaiRx, Inc.

6580
Classifica tra le azioni #25842
TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a... TaiRx, Inc., established in 2011 and headquartered in Taipei City, Taiwan, is a pharmaceutical company dedicated to the research, development, and commercialization of therapeutic solutions for cancer and other diseases. The company's clinical pipeline includes CVM-1118, an oral anti-cancer drug currently undergoing Phase II clinical trials, and Rexis, an add-on injection therapy for sepsis patients, which is in Phase III trials. In its pre-clinical stage, TaiRx is developing TRX-711 for secondary hyperparathyroidism, TRX-920 as an oral delivery formulation, and TRX-105, a molecule designed to treat and alleviate symptoms of various types of colitis. Beyond its developmental drugs, TaiRx also offers Zelnite, a medication that helps maintain patients' blood selenium levels and supports their immune systems. The company's future endeavors also involve the development of nodal diagnostic devices and innovative antibody-based drugs.
Prezzo delle azioni
$0.40861751
Capitalizzazione di mercato
$45.81M
Variazione (1 giorno)
-1.15%
Variazione (1 anno)
-46.41%
Paese
TW
Scambia TaiRx, Inc. (6580)

Categoria

EPS per TaiRx, Inc. (6580)
EPS al 2026 TTM: 0
Secondo gli ultimi rapporti finanziari e il prezzo delle azioni di TaiRx, Inc., l’EPS attuale della società (TTM) è 0. Alla fine del 2026, la società aveva un EPS di 0 uguale a rispetto a quello del 2026, che era di 0.
Storico EPS per TaiRx, Inc. da 2026 a 2026
EPS alla fine di ogni anno
Anno EPS Cambia
Non abbastanza dati per le date fornite.
EPS per aziende simili o concorrenti
Azienda EPS Differenza di EPS Il paese
$17.32 -
US
$27.74 -
NL
$2.98 -
AU
- -
CH
$-7.98 -
US